English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Esophageal cancer (EC) is the sixth leading cause of cancerrelated death worldwide (509,000 deaths in 2018), mainly categorized into adenocarcinoma (AC) and squamous cell carcinoma (SCC) (1), which differ in their pathology, tumor location, and prognosis. In contrast to other tumors, the esophagus has rich blood supply and regional lymph node drainage and is closely related to the adjacent anatomy, has a proclivity for earlier lymphatic spread and is associated with a poorer prognosis (2). Patients with EC who underwent surgery as the sole treatment had a median survival ranging from 13 to 19 months and a 5-year survival rate from 15% to 24% (3). The complex features of EC lead to the loss Original Article

Application of next-generation sequencing in resistance genes of neoadjuvant chemotherapy for esophageal cancer